Genetic Manipulation of Sirtuin 3 Causes Alterations of Key Metabolic Regulators in Melanoma

Chandra K Singh1, Jasmine George1, Gagan Chhabra1

  • 1Department of Dermatology, University of Wisconsin, Madison, WI, United States.

Insights

Mitochondrial sirtuin 3 (SIRT3) promotes melanoma cell proliferation by regulating metabolism. Inhibiting SIRT3 reduces tumor growth and alters glucose metabolism, offering a potential therapeutic strategy for melanoma.

Area of Science:

  • Mitochondrial biology
  • Cancer research
  • Melanoma pathogenesis

Background:

  • Mitochondrial sirtuin 3 (SIRT3) is crucial for cellular metabolism and energy production.
  • SIRT3 is upregulated in melanoma and its inhibition shows anti-proliferative effects.
  • Further validation of SIRT3's role in melanocytic cell proliferation and metabolic regulation is needed.

Purpose of the Study:

  • To validate and establish the pro-proliferative function of SIRT3 in melanocytic cells.
  • To investigate the mechanisms of SIRT3's action, focusing on metabolic regulation.
  • To assess the therapeutic potential of SIRT3 inhibition in melanoma.

Main Methods:

  • SIRT3 knockdown and overexpression strategies were employed in melanoma cell lines (G361, Hs294T, SK-MEL-2).
  • Tumorigenesis was assessed in immunodeficient mouse xenografts.
  • Gene expression analysis of glucose and glycogen metabolism was performed using PCR array and Ingenuity Pathway Analysis (IPA).

Main Results:

  • SIRT3 knockdown diminished tumorigenesis, while SIRT3 overexpression increased tumor growth in xenografts.
  • SIRT3 modulation affected markers of proliferation (PCNA), survival (Survivin), and angiogenesis (VEGF).
  • SIRT3 knockdown altered 37 genes involved in glucose and glycogen metabolism, impacting cell viability, proliferation, ROS, and apoptosis.

Conclusions:

  • SIRT3 plays a pro-proliferative role in melanoma by regulating cellular metabolism.
  • SIRT3 inhibition impacts glucose metabolism and imparts an anti-proliferative response.
  • Targeting SIRT3 represents a promising therapeutic strategy for melanoma management.